Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics

Alcoholism: Clinical and Experimental Research

Volumn 32, Issue 3, 2008, Pages 498-504

  Lucey, Michael R ^a,d   Silverman, Bernard L ^b   Illeperuma, Ari ^b   O'Brien, Charles P ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ALKERMES INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Alcohol Dependence; Injectable Naltrexone; Liver Chemistry Tests; Liver Injury; Randomized Clinical Study

Indexed keywords

NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HEPATOMEGALY; HUMAN; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED RELEASE PREPARATION;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NALTREXONE;

EID: 39749147912     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2007.00593.x     Document Type: Article

References (29)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington, DC.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE Study: a randomized controlled trial. JAMA 295 : 2003 2017.
3. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustaffsson L, Halldin J, Nilsson LH, Stolt G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27 : 1142 1149.
4. Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS (2003) Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 28 : 1973 1982.
5. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Croce L, Sasso F, Pozzato G, Cristianini G, Brandi G (1997) Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 41 : 845 850.
6. Bouza C, Angeles M, Munoz A, Amate JM (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99 : 811 828.
7. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35 : 587 593.
8. Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 54 : 1130 1135.
9. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC (2006) Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 30 : 480 490.
10. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group. (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 : 1617 1625.
11. Gastpar M, Bonnet U, Böning J, Mann K, Schmidt L, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22 : 592 598.
12. ®) in patients with alcohol dependence. Alcohol Clin Exp Res 28 : 1356 1361.
13. Kim SW, Grant JE, Adson DE, Remmel RP (2001a) A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol 21 : 632 634.
14. Kim SW, Grant JE, Shin YC (2001b) Double-blind naltrexone and placebo comparison study the treatment of pathological gambling. Biol Psychiatry 49 : 914 921.
15. Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP (2006) Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol 29 : 77 79.
16. Kranzler HR, Wesson DR, Billot L (2004) Naltrexone depot for the treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28 : 1051 1059.
17. National Institute on Alcohol Abuse and Alcoholism, Alcohol Alert No 42. October 1998. Available at : http://pubs.niaaa.nih.gov/publications/aa42.htm. Accessed June 2006.
18. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49 : 881 887.
19. Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE (1986) Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67 : 66 72.
20. Rehm J, Gmel G, Sempos CT, Trevisan M (2003) Alcohol-related morbidity and mortality. Alcohol Res Health 27 : 39 51.
21. ReVia PI (2006) ReVia (naltrexone) Package Insert. DuPont (US), Wilmington, DE.
22. Roozen HG, de Waart R, van der Windt DA, van den Brink W, de Jong CA, Kerkhof AJ (2006) A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 16 : 311 323.
23. Tome S, Lucey MR (2004) Current management of alcoholic liver disease. Aliment Pharmacol Ther 19 : 707 714.
24. Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC (2005) Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 45 : 1259 1267.
25. United States Food and Drug Administration. Safety concerns associated with over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use. 2004. Available at : http://www.fda.gov/cder/drug/ analgesics/SciencePaper.htm. Accessed February 2007.
26. Verebey KG, Mule SJ (1986) Naltrexone (Trexan): a review of hepatotoxicity issues. NIDA Res Monogr 67 : 73 81.
27. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 : 876 880.
28. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (2001) Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. The Guilford Press, New York, NY.
29. Yen MH, Ko HC, Tang FI, Lu RB, Hong JS (2006) Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol 38 : 117 120.